, China

Sino Biopharma records $1,852m revenue in H1

Earnings per share were 5.2% higher than that of the same period last year.

Chinese pharmaceutical conglomerate Sino Biopharmaceutical Limited (Sino Biopharma) has recorded a total revenue of $1,852.32m from January to June, which was 1% higher than the total revenue of H1 2019. Profit attributable to the owners of the parent was approximately $177.65m – 16% lower than that of the same period last year.

The decrease was mainly impacted by the non-cash fair value loss of and effective interest expenses from the $886.69m zero coupon convertible bonds due 2025 that the group issued in February 2020. Excluding the impact of amortisation expenses of new identifiable intangible assets arising from the acquisition of 24% interests in Beijing Tide (net of related deferred tax and non-controlling interests), the unrealised fair value losses (net) on equity investments and financials assets, fair value loss of convertible bond embedded derivative component and effective interest expenses of convertible bond debt component, underlying profit was approximately $257.90m, approximately 5.2% higher than that of the same period last year.

Based on underlying profit, the earnings per share were approximately 2.05 cents. The group claimed to maintain a strong financial position with cash and bank balances reaching approximately $2,503m at the period end.

Sino Biopharma has attributed their interim results mainly to the implementation of the prices in the National Reimbursement Drug List and the centralised drug procurement policy. The sales of oncology medicines made up the most portion of the group’s revenue (31.8%) whilst hepatitis (17.8%), orthopedic (8%), anti-infectious medicines (6%), and respiratory system medicines (4.7%), all had their fair shares, the press release added.

Since you're here...

...there are many ways you can work with us to advertise your company and connect to your customers. Our team can help you dight and create an advertising campaign, in print and digital, on this website and in print magazine.

We can also organize a real life or digital event for you and find thought leader speakers as well as industry leaders, who could be your potential partners, to join the event. We also run some awards programmes which give you an opportunity to be recognized for your achievements during the year and you can join this as a participant or a sponsor.

Let us help you drive your business forward with a good partnership!

Get Health Care Asia Magazine in your inbox
It was recognised for its cutting-edge medical device packaging design, Dispenser Integrated System Kit (DISK).
There has been an expanding research base across India, China, and Japan.
It combines third-party assured data verification with blockchain technology.
Consultation is available for only $0.014 (INR1).
The number of hospitals operating on hip fracture that have access to a fracture liaison service has been steadily rising from 2013 to 2020.
GMT Manila’s award-winning initiative, in collaboration with Endec Inc. and Scilore LLC, is a rapidly deployable turnkey solution for RT-PCR Testing that made it more available across the Philippines. 
As The National Cardiovascular Referral Center in Indonesia, NCCHK has been acknowledged by Asia's Healthcare Industry.
Currently, North America dominates the market across the globe.
More medical devices are being bought for home use.
It has also introduced a new hotline service.
The firm was recognised for its multiple initiatives in braving the COVID-19 crisis.
It took home the Training Initiative of the Year trophy for its non-invasive therapy treatment for benign prostatic hyperplasia (BPH).
The country’s SII makes up about half of Covax supply.
It owns 39 hospitals and eight clinics across England, Wales, and Scotland.
The company plans to set up over 100 in-school clinics.